Want to see HK:0460 full AI Analyst Report?
Top Page
Sihuan Pharmaceutical Holdings Group
(0460)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$0.72
▼(-8.08% Downside)
Action:Reiterated
Date:10/15/26
The score is held back primarily by weak cash-flow quality and inconsistent free cash flow, despite the 2025 earnings rebound and a comparatively manageable balance sheet. Technicals add additional pressure due to a clear downtrend and negative MACD. Valuation is roughly neutral (moderate P/E and modest yield), offering limited offset to the cash-flow and trend risks.
Positive Factors
Revenue Recovery
The sharp 2025 revenue rebound and return to profitability show that the business can regain operating momentum after a difficult period. If this recovery persists, greater sales scale should support reinvestment in pharmaceutical commercialization and improve earnings capacity over the next several quarters.
Negative Factors
Weak Cash Generation
Negative operating and free cash flow alongside positive net income points to weak earnings conversion and reduces internally generated funding. If sustained, this could constrain investment in products and commercialization, increase reliance on external financing, and weaken financial flexibility despite manageable leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The sharp 2025 revenue rebound and return to profitability show that the business can regain operating momentum after a difficult period. If this recovery persists, greater sales scale should support reinvestment in pharmaceutical commercialization and improve earnings capacity over the next several quarters.
Read all positive factors
Sihuan Pharmaceutical Holdings Group (0460) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.76B
Dividend Yield1.5%
Average Volume (3M)18.53M
Price to Earnings (P/E)18.4
Beta (1Y)1.09
Revenue Growth29.68%
EPS GrowthN/A
CountryHK
Employees2,843
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.03
Shares Outstanding9,329,999,000
10 Day Avg. Volume20,571,852
30 Day Avg. Volume18,533,507
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)1.72
Price to Sales (P/S)3.85
P/FCF Ratio-46.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$1.11Price Target Upside42.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$3.44B
Sihuan Pharmaceutical Holdings Group Business Overview & Revenue Model
Company Description
Sihuan Pharmaceutical Holdings Group Ltd. is an investment holding company that engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products. Its portfolio includes products for the cardio-cerebral v...
How the Company Makes Money
Sihuan Pharmaceutical makes money primarily by selling pharmaceutical products in the PRC. Its revenue model is driven by: (1) Product sales: The core revenue stream comes from sales of prescription drugs manufactured by the group and distributed ...
Sihuan Pharmaceutical Holdings Group Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.63B | 2.62B | 1.90B | 1.86B | 2.18B | 3.04B |
| Gross Profit | 1.73B | 1.80B | 1.24B | 1.30B | 1.49B | 2.43B |
| EBITDA | 697.59M | 702.00M | -130.98M | 334.31M | -1.54B | 985.56M |
| Net Income | 301.80M | 179.70M | -216.66M | -54.02M | -1.91B | 416.51M |
Balance Sheet | ||||||
| Total Assets | 11.63B | 11.64B | 10.53B | 11.54B | 12.14B | 14.50B |
| Cash, Cash Equivalents and Short-Term Investments | 3.72B | 3.98B | 3.63B | 4.48B | 4.79B | 5.79B |
| Total Debt | 969.22M | 1.01B | 942.76M | 1.26B | 1.29B | 1.08B |
| Total Liabilities | 4.67B | 4.73B | 5.58B | 6.40B | 6.50B | 5.35B |
| Stockholders Equity | 6.15B | 5.85B | 4.37B | 4.43B | 4.74B | 8.28B |
Cash Flow | ||||||
| Free Cash Flow | -94.29M | -218.06M | 57.51M | -95.93M | -355.97M | 64.28M |
| Operating Cash Flow | -15.97M | -23.56M | 243.89M | 199.49M | 46.49M | 665.29M |
| Investing Cash Flow | 295.78M | -296.48M | 758.24M | 169.88M | -1.66B | -337.57M |
| Financing Cash Flow | -423.09M | 358.16M | -1.26B | -419.56M | -238.93M | 750.66M |
Sihuan Pharmaceutical Holdings Group Technical Analysis
Neutral
0.78
Price Trends
0.75
Negative
0.82
Negative
1.07
Negative
Market Momentum
>-0.01
Negative
48.87
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0460, the sentiment is Neutral. The current price of 0.78 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.75, and below the 200-day MA of 1.07, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.87 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0460.
Sihuan Pharmaceutical Holdings Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$26.72B | 16.30 | 11.32% | 6.71% | -9.56% | -23.22% | |
68 Neutral | HK$29.12B | 6.18 | 7.92% | 5.17% | 7.94% | 52.83% | |
61 Neutral | HK$23.94B | 13.43 | 8.60% | 3.50% | 14.80% | -2.88% | |
57 Neutral | HK$35.32B | 14.74 | 5.57% | 6.71% | 6.00% | -23.05% | |
56 Neutral | HK$65.63B | 17.04 | 7.14% | 2.73% | 9.88% | 9.30% | |
52 Neutral | HK$6.76B | 18.42 | 5.03% | 1.50% | 29.68% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:0460
Sihuan Pharmaceutical Holdings Group
0.73
-0.74
-50.38%
HK:0867
China Medical System Holdings
9.82
-3.24
-24.82%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
12.86
-4.81
-27.23%
HK:1513
Livzon Pharmaceutical Group
23.18
-4.60
-16.55%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
16.47
-6.72
-28.97%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.64
-0.09
-1.86%
Sihuan Pharmaceutical Holdings Group Corporate Events
Sihuan Pharmaceutical Invests in Canton Biologics to Build Full-Chain Regenerative Aesthetics Platform
Oct 8, 2026
Sihuan Pharmaceutical, via its subsidiary Meiyan Space Biotechnology, has completed a strategic equity investment in Guangzhou Canton Biologics and agreed to jointly commercialize full-length triple-helix recombinant human collagen raw materials. ...
Sihuan Pharmaceutical Expands Dongyan Skin Booster Dosage Range to Strengthen Aesthetics Portfolio
Oct 5, 2026
Sihuan Pharmaceutical’s subsidiary Meiyan Space has received Chinese regulatory approval for five new dosage specifications of its Dongyan hyaluronic acid-based skin booster. Dongyan, formulated with hyaluronic acid, L-carnosine, amino acids...
Sihuan’s Xuanzhu Biopharm Strikes Exclusive Bireociclib Deal in Thailand
Sep 3, 2026
Sihuan Pharmaceutical’s non-wholly owned subsidiary Xuanzhu Biopharm has signed a tri-party commercial agreement with Thailand’s Innobic (Asia) and ZaoAn International for the exclusive commercialization of Bireociclib tablets in Thail...
Sihuan Pharmaceutical Grants 116 Million Performance-Based Share Awards
Sep 1, 2026
Sihuan Pharmaceutical Holdings Group has granted 116,150,000 share awards under its 2026 Share Incentive Scheme, equivalent to about 1.27% of its issued share capital, to a mix of executive management, related persons and 104 other employees. The ...
Sihuan Pharma Launches Share Buyback as Profit Surges on Aesthetics Push
Aug 27, 2026
Sihuan Pharmaceutical Holdings Group has stepped up its capital management by repurchasing 10 million shares on the open market at an average price of HK$0.8111 per share, representing about 0.11% of its issued share capital, with the stock to be ...
Sihuan Pharmaceutical Reshapes Leadership With CFO Exit and New Non-Executive Director
Aug 26, 2026
Sihuan Pharmaceutical announced that Ms. Miao Guili has resigned as executive director, deputy chief executive officer and chief financial officer, as well as co-chair of the board’s risk management committee, effective 26 August 2026, citin...
Sihuan Pharmaceutical Clarifies Board and Committee Structure
Aug 26, 2026
Sihuan Pharmaceutical Holdings Group Ltd. has announced the current composition of its board of directors, detailing the roles of its executive, non-executive and independent non-executive members. The disclosure also specifies membership and chai...
Sihuan Pharmaceutical Leans on Aesthetics and Innovation as Generic Drug Margins Erode
Aug 26, 2026
Sihuan Pharmaceutical reported interim revenue of RMB1,161.2 million for the six months ended 30 June 2026, up 1.3% year on year, as robust growth in medical aesthetics and innovative medicines offset sharp declines in generic drug sales. Medical ...
Sihuan Pharmaceutical Sets Board Meeting to Approve Interim Results and Dividend Plan
Aug 14, 2026
Sihuan Pharmaceutical Holdings Group Ltd., incorporated in Bermuda and listed in Hong Kong, operates in the pharmaceutical sector and markets its products mainly through its subsidiaries in regional healthcare markets. Its governance framework com...
Sihuan Pharmaceutical Updates Bermuda Registered Office Address
Jul 27, 2026
Sihuan Pharmaceutical Holdings Group Ltd. has announced that, effective 3 August 2026, its registered office and principal share registrar address in Bermuda will move to Richmond House, 12 Par-la-Ville Road, Hamilton HM 08. The company’s Ho...
Sihuan Pharmaceutical Flags 217% Profit Surge on Medical Aesthetics and Portfolio Gains
Jul 27, 2026
Sihuan Pharmaceutical has issued a positive profit alert for the six months ended 30 June 2026, indicating revenue of at least RMB1,140 million, roughly flat year-on-year, but a net profit of no less than RMB210 million, representing a surge of at...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.